Glucotrack Completes Second Long-Term Preclinical Study For Its Continuous Blood Glucose Monitor, Demonstrating Mean Absolute Relative Difference Of 4.7% At Day 90
Portfolio Pulse from Benzinga Newsdesk
Glucotrack has completed its second long-term preclinical study for its continuous blood glucose monitor, showing a mean absolute relative difference of 4.7% at day 90.
June 05, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Glucotrack's successful completion of its second long-term preclinical study for its continuous blood glucose monitor, with a mean absolute relative difference of 4.7% at day 90, is a positive development for the company.
The successful completion of the preclinical study with a favorable outcome (mean absolute relative difference of 4.7% at day 90) indicates progress in product development, which is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100